Greenbrook
Mclean
About Greenbrook
Greenbrook TMS owns and operates healthcare centers providing repetitive transcranial magnetic stimulation therapy (TMS) for the treatment of major depressive disorder (MDD) and other neurological diseases. Local electromagnetic stimulation is given during TMS therapy to certain brain areas known to be directly involved in mood regulation. Spravato is promoted to treat depressive symptoms in adults with MDD who have suicidal thoughts or behaviors as well as adults with treatment-resistant depression. In order to give patients a thorough treatment experience, Greenbrook handles insurance coverage and handles logistics while keeping the clients informed and involved in the procedure.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $121.6M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2024)
- Ticker: tsx:GTMS
- Website: greenbrooktms.com
- Phone: 866.928.6076
Industries & Categories
Health Care, Medical, Neuroscience, Psychology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/greenbrook-178290 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.